Locally controlled release of immunosuppressive promotes survival of transplanted adult spinal cord tissue. (5th December 2022)

• Record Type: Journal Article
• Authors: Wang, Ziqiang; Li, Ya; Sun, Chenxuan; Cui, Pukong; Han, Yuanyuan; Wu, Tong; Xu, Bai; Zhang, Can; Shi, Liyang; Dai, Jianwu
• Is Part Of: Regenerative biomaterials. Volume 10(2023)
• Publication Date: 2022-12-05
• Subjects: spinal cord injury -- adult spinal cord tissue transplantation -- immune rejection -- controlled release -- tacrolimus; Biomedical materials -- Periodicals; Regenerative medicine -- Periodicals; 610.284
• DOI: 10.1093/rb/rbac097
• Languages: English
• ISSNs: 2056-3418

Abstract

Abstract: Transplantation of adult spinal cord tissue (aSCT) is a promising treatment for spinal cord injury (SCI) basing on various types of neural cells and matrix components inside aSCT. However, long-term systemic administration of immunosuppressors (e.g. tacrolimus, TAC) is required for the survival of allogeneic tissue, which often associated with severe side effects such as infection, liver damageand renal failure. In this study, a triglycerol monostearate (TGM)-based TAC delivery system (e.g. TAC@TGM) with high drug loading concentration was developed, which possessed injectable properties as well as sustainable and immune-responsive drug release behaviors. In complete transected SCI model, locally injected TAC@TGM could reduce the infiltration of inflammation cells, enhance the survival of transplanted aSCT (e.g. Tuj-1 + and NF + neurons) and promote the recovery of locomotor function. Moreover, controlled release of TAC by TAC@TGM attenuated side effects of TAC on liver and kidneys compared with traditional systemic administration. More importantly, the developed TAC@TGM system provided a facile single dose of long-term immunosuppressive effect not just for aSCT transplantation, but also for other tissue/organ and cell transplantations. Graphical abstract: